Abiomed's heart pump gets EU nod

Thu Apr 12, 2012 6:30pm IST

A zoomed picture shows two surgeons performing an operation to implant an artificial heart valve in the operating room of a Berlin hospital August 15, 2003. REUTERS/Fabrizio Bensch

A zoomed picture shows two surgeons performing an operation to implant an artificial heart valve in the operating room of a Berlin hospital August 15, 2003.

Credit: Reuters/Fabrizio Bensch

Related Topics

Stocks

   

(Reuters) - Abiomed Inc said European health regulators approved the use of its heart pump in cardiac surgery.

The Danvers, Massachusetts-based company said the device, called Impella cVAD, is expected to be commercially available in Europe by this summer.

The device is intended for use in cardiac surgery for supporting the weakened heart's left ventricle, which is responsible for pumping oxygen-rich blood from the lungs throughout the body.

Impella cVAD is still not approved in the United States.

Abiomed shares closed at $20.90 on Wednesday on the Nasdaq.

(Reporting by Anand Basu in Bangalore; Editing by Viraj Nair)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Interview

REUTERS SHOWCASE

No Relief

No Relief

Paracetamol no better than placebo for low back pain, study finds.  Full Article 

Fighting AIDS

Fighting AIDS

Bill Clinton says AIDS-free generation 'within reach'.  Full Article 

Obamacare Enrollment

Obamacare Enrollment

Over 10 million U.S. adults gain coverage under Obamacare: study.  Full Article 

Quality Issue

Quality Issue

Ipca halts U.S. shipments from Ratlam plant after FDA finds violations.  Full Article 

Financial Cost

Financial Cost

Abuse of U.S. generic-drug rules costs billions: report.  Full Article 

Fitness Hooping

Fitness Hooping

Hoopsters put circus-inspired spin on cardio workout.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage